All In Biotech

Drug Trial Radar · NCT07030595

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

A Randomized, Open-Label, Multi-Center, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 474 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

474

Actual

Start

Jun 12, 2023

Primary completion

Oct 2, 2024

Study completion May 30, 2025

Sponsor

Lead sponsor
Alebund PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese patients with hyperphosphatemia.

Conditions

  • ESRD (End Stage Renal Disease)
  • Chronic Kidney Disease(CKD)
  • Hyperphosphatemia
  • Hyperphosphatemia in Chronic Kidney Disease
  • Dialysis
  • Chronic Kidney Disease, Receiving Dialysis

Interventions

  • AP301Drug

    Three times a day, administered orally with three meals at a daily dose level from 2.1g to 9.1g

  • Sevelamer carbonate (Renvela®)Drug

    Three times a day, administered orally with three meals at a daily dose level from 2.4g to 9.6g

  • AP301 Low DoseDrug

    Three times a day, administered orally with three meals at a daily dose level of 0.375g.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in serum phosphorus levels between AP301 and AP301 low dose groups in hyperphosphatemic patientsTime frame: From the end of Week 24 to the end of Week 27
  2. Change in serum phosphorus levels between AP301 and sevelamer carbonate groups in hyperphosphatemic patientsTime frame: From Baseline to the end of Week 12

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Jishuitan Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Peking University International Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China

  • Jilin Province People's Hospital

    Jilin City, Changchun, China

  • The Second Norman Bethune Hospital of Jilin University

    Jilin City, Changchun, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Dongguan People's Hospital

    Guangzhou, Guangdong, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • The First People's Hospital of Nanning

    Nanning, Guangxi, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital Of Xingtai Medical College

    Xingtai, Hebei, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hospital of Universal Love

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Changzhou NO.2 People's Hospital

    Changzhou, Jiangsu, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Jiangsu Province Hosipital

    Nanjing, Jiangsu, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Dalian Municipal Central Hospital

    Dalian, Liaoning, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.